Experiences from treating seven adult 5q spinal muscular atrophy patients with Nusinersen

Background:The antisense oligonucleotide Nusinersen recently became the first approved drug against spinal muscular atrophy (SMA). It was approved for all ages, albeit the clinical trials were cond...